252722-52-4

Basic information

• Product Name: 4-(1-PIPERAZINYL)-1H-PYRROLO[2,3-D]PYRIMIDINE
• Synonyms: 4-(1-PIPERAZINYL)-1H-PYRROLO[2,3-D]PYRIMIDINE;1-{7H-pyrrolo[2,3-d]pyrimidin-4-yl}piperazine;4-(piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine
• CAS NO: 252722-52-4
• Molecular Formula: C₁₀H₁₃N₅
• Molecular Weight: 203.24
• Mol File: 252722-52-4.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Density: 1.297g/cm³
• Refractive Index: 1.666
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-(1-PIPERAZINYL)-1H-PYRROLO[2,3-D]PYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(1-PIPERAZINYL)-1H-PYRROLO[2,3-D]PYRIMIDINE(252722-52-4)
• EPA Substance Registry System: 4-(1-PIPERAZINYL)-1H-PYRROLO[2,3-D]PYRIMIDINE(252722-52-4)

Safety Data

• Hazardous Substances Data: 252722-52-4(Hazardous Substances Data)

Usage

General Description

4-(1-piperazinyl)-1H-pyrrolo[2,3-d]pyrimidine is a chemical compound that belongs to the class of pyrrolopyrimidine derivatives. It is a heterocyclic compound containing a pyrrolo[2,3-d]pyrimidine core with a piperazine moiety attached at the 4-position. 4-(1-PIPERAZINYL)-1H-PYRROLO[2,3-D]PYRIMIDINE has demonstrated pharmaceutical potential, particularly in the field of medicinal chemistry. It has been studied for its potential use in the treatment of various diseases and conditions, including cancer and neurological disorders. Its unique structure and potential biological activities make it a subject of interest for further research and development in the pharmaceutical industry.

InChI:InChI=1/C10H13N5/c1-2-12-9-8(1)10(14-7-13-9)15-5-3-11-4-6-15/h1-2,7,11H,3-6H2,(H,12,13,14)

Upstream product

• 110-85-0 piperazine 
• 3680-69-1 4-chloro-1H-pyrrolo[2,3-d]pyrimidine 
• 1248587-70-3 tert-butyl 4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperazine-1-carboxylate 

Relevant articles and documents

Efficient photocaging of a tight-binding bisubstrate inhibitor of cAMP-dependent protein kinase

Photocaging of a tight-binding bisubstrate inhibitor of cAMP-dependent protein kinase (PKA) with a nitrodibenzofuran-based group fully abolished its inhibitory potency. The affinity difference between the photocaged and the active inhibitor was over 5 orders of magnitude. The photocaged inhibitor disrupted the PKA holoenzyme in cell lysates upon photolysis under a 398 nm LED.

AXL KINASE INHIBITORS

Axl kinase inhibitory compounds are disclosed, as well as compositions and methods of using the same in the treatment of cancer and other conditions mediated by and/or associated with Axl kinase.